Tafamidis Meglumine (Vyndaqel)

Key Messages

• CADTH recommends that Vyndaqel should be reimbursed by public drug plans for the treatment of transthyretin-mediated amyloidosis (ATTR) if certain conditions are met.
• Vyndaqel should only be covered to treat adult patients who have a documented diagnosis of cardiomyopathy caused by ATTR. The type of ATTR cardiomyopathy could be either hereditary (inherited) or wild type (patients without a family history of the disease). Patients who are eligible for Vyndaqel coverage must also have a New York Heart Association (NYHA) classification of I to III and a history of heart failure. Patients who have received a heart transplant or a cardiac mechanical assist device (CMAD) or who are taking other disease-modifying treatments for ATTR are not eligible for reimbursement of Vyndaqel.
• Vyndaqel should only be reimbursed for patients with ATTR if they are being cared for by a specialist for the condition and if the price of Vyndaqel is reduced.